NCT00790816 - Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | Biotech Hunter

Enrollment

500

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 19, 2016

Study Completion Date

August 19, 2016

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib in combination with an anti-cancer agent

Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI

DRUG

Lapatinib

Lapatinib monotherapy

DRUG

Lapatinib in combination with an anti-cancer agent as specified by parent protocol

Trial Locations (23)

14263

Novartis Investigative Site, Buffalo

20007

Novartis Investigative Site, Washington D.C.

27710

Novartis Investigative Site, Durham

29605

Novartis Investigative Site, Greenville

30341

Novartis Investigative Site, Atlanta

33916

Novartis Investigative Site, Fort Myers

37203

Novartis Investigative Site, Nashville

38120

Novartis Investigative Site, Memphis

44106

Novartis Investigative Site, Cleveland

48202

Novartis Investigative Site, Detroit

84112

Novartis Investigative Site, Salt Lake City

85259

Novartis Investigative Site, Scottsdale

85724

Novartis Investigative Site, Tucson

90404

Novartis Investigative Site, Santa Monica

03756

Novartis Investigative Site, Lebanon

T6G 1Z2

Novartis Investigative Site, Edmonton

H2W 1T8

Novartis Investigative Site, Montreal

1066 CX

Novartis Investigative Site, Amsterdam

110-744

Novartis Investigative Site, Seoul

120-752

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

138-736

Novartis Investigative Site, Songpa-gu, Seoul

08907

Novartis Investigative Site, Hospitalet de Llobregat (Barcelona)